Politan Capital Management said its candidates captured two board seats in Thursday’s shareholder vote, citing a preliminary analysis.

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

PET radiotracers facilitate the visualization of amyloid plaque density, enabling clinicians to assess people with cognitive impairment for Alzheimer’s and evaluate their response to treatment.

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

In April, a Securities and Exchange Commission filing revealed that Wojcicki planned to take the company private. 23andMe’s stock price had fallen below $1 per share at the time, down from its $10 ...

Koffey was elected to Masimo’s board in June 2023 along with Politan-backed candidate Michelle Brennan, a former Johnson & Johnson executive. The hedge fund argued that Masimo’s $1 billion acquisition ...

DiveWire guarantees visibility for your news announcements through instant distribution to MedTech Dive’s audience and its 56,000 newsletter subscribers for 21 days.

Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.

Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions.

The FDA said the problems “raise concerns about the quality and integrity of data generated by the labs,” which provide third-party testing and validation data services for device firms.

Senseonics and commercial partner Ascensia Diabetes Care received clearance from the Food and Drug Administration for the first implantable glucose sensor that can be worn for one year, doubling the ...